Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athenex, Inc. stock logo
ATNX
Athenex
$0.95
$0.20
$23.80
$1.76M1.36194,316 shs1.88 million shs
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$3.31
+0.2%
$3.12
$1.27
$9.47
$10.79M1.551.28 million shs19,378 shs
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
$4.82
-0.2%
$5.04
$1.62
$29.28
$9.17M1.81.52 million shs12,767 shs
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
$1.21
+0.4%
$1.06
$0.58
$3.80
$15.98M0.673.73 million shs132,991 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athenex, Inc. stock logo
ATNX
Athenex
0.00%0.00%0.00%0.00%0.00%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
0.00%+10.94%+4.26%+32.20%+46.89%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
0.00%+2.34%-1.43%+13.41%+481,999,900.00%
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
0.00%+6.64%-0.41%+43.47%+34.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Athenex, Inc. stock logo
ATNX
Athenex
0.1279 of 5 stars
0.00.00.04.10.00.00.0
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
1.1605 of 5 stars
3.50.00.00.00.00.00.6
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
1.4362 of 5 stars
3.62.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athenex, Inc. stock logo
ATNX
Athenex
0.00
N/AN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
0.00
N/AN/AN/A
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
3.00
Buy$10.00107.47% Upside
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
3.25
Buy$4.00231.95% Upside

Current Analyst Ratings Breakdown

Latest ATNX, HOTH, CYCN, and DWTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
6/12/2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
4/23/2025
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$10.00
4/15/2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athenex, Inc. stock logo
ATNX
Athenex
$102.82M0.00N/AN/A($3.07) per share0.00
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2M5.30N/AN/A$3.27 per share1.01
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/A($7.56) per shareN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/AN/AN/AN/A$0.86 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athenex, Inc. stock logo
ATNX
Athenex
-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$3.06M-$1.16N/AN/AN/A-34.02%-30.68%8/6/2025 (Estimated)
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$12.35M-$18.04N/AN/AN/AN/AN/A-34.74%8/6/2025 (Estimated)
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
-$8.19M-$1.14N/AN/AN/AN/A-109.18%-100.22%8/8/2025 (Estimated)

Latest ATNX, HOTH, CYCN, and DWTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
-$0.34-$0.27+$0.07-$0.27N/AN/A
5/8/2025Q1 2025
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$0.77-$4.21-$3.44-$8.45N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Athenex, Inc. stock logo
ATNX
Athenex
N/AN/AN/AN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/A
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/AN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athenex, Inc. stock logo
ATNX
Athenex
3.08
1.09
0.72
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A
4.21
4.21
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/A
7.43
7.43
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/A
15.09
15.08

Institutional Ownership

CompanyInstitutional Ownership
Athenex, Inc. stock logo
ATNX
Athenex
30.48%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
75.62%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
9.05%
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
7.08%

Insider Ownership

CompanyInsider Ownership
Athenex, Inc. stock logo
ATNX
Athenex
9.20%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
34.30%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
3.90%
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
6.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
Athenex, Inc. stock logo
ATNX
Athenex
6528.66 million7.87 millionOptionable
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
303.21 million2.11 millionNo Data
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
51.91 million1.84 millionN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
413.21 million12.30 millionNot Optionable

Recent News About These Companies

HOTH THERAPEUTICS INC - FinanzNachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Athenex stock logo

Athenex NASDAQ:ATNX

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Cyclerion Therapeutics stock logo

Cyclerion Therapeutics NASDAQ:CYCN

$3.30 +0.01 (+0.15%)
As of 07/3/2025 02:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Dogwood Therapeutics stock logo

Dogwood Therapeutics NASDAQ:DWTX

$4.82 -0.01 (-0.21%)
Closing price 07/3/2025 03:00 PM Eastern
Extended Trading
$4.80 -0.02 (-0.31%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Hoth Therapeutics stock logo

Hoth Therapeutics NASDAQ:HOTH

$1.20 +0.01 (+0.42%)
Closing price 07/3/2025 03:36 PM Eastern
Extended Trading
$1.20 0.00 (0.00%)
As of 07/3/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.